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Summary
Computational models represent a highly suitable framework, not only for testing biological hypotheses and generating new ones but
also for optimising experimental strategies. As one surveys the literature devoted to cancer modelling, it is obvious that immense
progress has been made in applying simulation techniques to the study of cancer biology, although the full impact has yet to be realised.
For example, there are excellent models to describe cancer incidence rates or factors for early disease detection, but these predictions are
unable to explain the functional and molecular changes that are associated with tumour progression. In addition, it is crucial that
interactions between mechanical effects, and intracellular and intercellular signalling are incorporated in order to understand cancer
growth, its interaction with the extracellular microenvironment and invasion of secondary sites. There is a compelling need to tailor new,
physiologically relevant in silico models that are specialised for particular types of cancer, such as ovarian cancer owing to its unique
route of metastasis, which are capable of investigating anti-cancer therapies, and generating both qualitative and quantitative predictions.
This Commentary will focus on how computational simulation approaches can advance our understanding of ovarian cancer progression
and treatment, in particular, with the help of multicellular cancer spheroids, and thus, can inform biological hypothesis and experimental
design.
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Introduction
Ovarian cancer remains an important health problem owing to its
high lethality; it has the highest mortality rate of all
gynaecological tumours and is the fifth leading cause of female
cancer deaths. This disease is referred to as a silent killer because
of its asymptomatic early stages (Le Page et al., 2004). Most
patients are diagnosed at an advanced stage of this disease, with
metastatic outgrowth beyond the ovary and poor survival
prognosis. Initially, patients respond to cytoreductive surgery
and a platinum- and taxane-based chemotherapy, but owing to the
occurrence of chemoresistance, there is only a cure rate of 30%
(Bast et al., 2009; Lengyel, 2010). Designing improved therapies
to achieve a long-term cure has remained a challenge because
little is known about the underlying mechanisms promoting
ovarian cancer progression, its tumour–stroma microenvironment
and how chemoresistance occurs (Agarwal and Kaye, 2003).
A set of intricate cellular interactions characterise the
biological nature of cancerous tissues, and the complex
crosstalk of these processes spans multiple scales, for which
mathematical simulation techniques can provide a systems-level
understanding (Fig. 1). The development of a virtual tool, which
integrates the disciplines of engineering and cell biology to create
a multiscale, patient-specific in silico representation of cancerous
cells and tissues is arguably the ultimate goal of this
interdisciplinary research area (Anderson and Quaranta, 2008;
Deisboeck et al., 2011; Kam et al., 2012). Such computational
models are designed to improve our knowledge of the
‘pathophysiological phenomena’ of cancer, to screen chemo-
and radiotherapeutics, and in some cases to help us develop
surgical strategies to arrest the growth of primary tumours and
disease progression to secondary sites (Brown and Palmer, 2009;
Kohandel et al., 2006; Montalenti et al., 1998; Panetta, 1997).
The majority of previous mathematical models have focused on
breast and prostate cancer, as both cancer types have the highest
incidence rates in females and males, respectively (Chakrabarti
et al., 2012; Jain et al., 2011; Siegel et al., 2012). However, there
are a few studies that mathematically model ovarian cancer and
address relevant aspects of tumour growth and angiogenesis,
which indicates the efficacy of predictive techniques in
hypothesis testing related to anti-cancer agents, such as cell-
cycle and non-cell-cycle-specific therapeutics (Brown and
Palmer, 2009; Kohandel et al., 2006; Montalenti et al., 1998;
Panetta, 1997).
The purpose of this Commentary is to provide an overview of
the pathogenesis of ovarian cancer, a review of experimental
approaches used to investigate the growth of cancer spheroids
and their microenvironment, and a consideration of mathematical
techniques used to predict tumour growth, treatment and disease
progression. We will also discuss simulation techniques used for
breast and prostate cancer, and address areas that are in need of
advancement for future research efforts, such as multiscale
modelling approaches and patient-specific input parameters.
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Pathogenesis of ovarian cancer
The aetiology of ovarian cancer is still incompletely understood.
Several risk factors, such as age, family history and nulliparity have
a role in the pathogenesis of this disease. Ovarian cancer is divided
into three subgroups – epithelial, stromal and germ cell tumours – of
which epithelial ovarian cancer (see Box 1) is the most common and
lethal type (Bast et al., 2009; Cannistra, 2004; Shih and Davidson,
2009). It has been postulated that ovarian carcinomas can develop
from any of four different origins: the ovarian surface epithelium,
the fallopian tube epithelium, cells lining subsurface inclusion cysts
or the peritoneal cavity (Bast et al., 2009; Cannistra, 2004). Direct
evidence for the possible fallopian tube origin has been provided
using a double knockout animal model with a reproductive tract-
specific deletion in the microRNA processing enzymeDicer and the
tumour suppressor phosphatase and tensin homologue (Pten). In this
animal study, ovarian carcinomas arise from the stromal
compartment of the fallopian tube rather than the epithelial layer
and show molecular characteristics that are similar to those seen in
patients (Kim et al., 2012).
Ovarian carcinomas have a unique route to metastasis through
the intraperitoneal dissemination of cancer cells within the
tumour (ascites) fluid. Cancer cells detach from the primary
tumour, either as single cells or multicellular spheroids, by
reorganising their cell–cell and/or cell–matrix adhesions, and
exerting cancer-associated proteolytic functions. These cells then
adhere to the mesothelial cell layer that covers the peritoneal
organs and invade into the underlying extracellular matrix
(ECM), where they grow secondary tumours. These events are
clearly the crucial steps that lead to poor patient outcomes
(Burleson et al., 2005; Dong et al., 2010; Moss et al., 2009;
Sawada et al., 2008; Symowicz et al., 2007). However, little is
known with regards to the underlying mechanisms that facilitate
metastasis and subsequently result in chemoresistance. Primary
tumours, their metastatic lesions and tumour xenografts have
similar gene expression patterns, which opens a therapeutic
window to target both the source of the primary tumour and the
metastatic lesion by developing novel anti-cancer agents
(Lengyel, 2010; Moss et al., 2009; Zietarska et al., 2007).
Macroscale
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Fig. 1. Integrated computational and experimental models of cancer from macroscale through to nanoscale. A set of intricate cellular interactions
characterise the biological nature of cancerous tissues and the complex crosstalk of these processes spans multiple scales, for which mathematical simulation
techniques can provide a systems-level understanding. Within each stream, mathematical predictions can be made by incorporating cancer-associated, cellular,
biomechanical and biochemical processes that occur across spatial scales ranging from the macro- to micro- and nanoscales. The multiscale modelling framework
depicted here represents a natural framework for testing biological hypotheses, generating new ones and optimising experimental design. The images (right
column) illustrate the different cellular scales used to apply computational and experimental models: a schematic and confocal micrograph of 3D co-cultures
represent the macroscale (cell actin filaments stained with rhodamine415-conjugated phalloidin, red), a scanning electron micrograph of the cancer cell network
indicates the microscale, and a confocal micrograph of a cancer spheroid shows the nanoscale (cell actin filaments stained with rhodamine415-conjugated
phalloidin, red; nuclei stained with 49,6-diamidino-2-phenylindole, blue; protein stain using respective primary and secondary Alexa488-conjugated
antibodies, green).
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These findings suggest that the spheroid population in the
peritoneal fluid represents the main source for intra-abdominal
outgrowth, and therefore, is a key target for anti-metastatic
therapies.
Experimental modelling of multicellular cancer
spheroids
Multicellular cancer spheroids link the tumour to the
development of microregions of heterogenous cells,
micrometastasis and an abnormal microenvironment. Crucial
differences in the cellular microenvironment occur over very
small distances of 10 to 20 cell diameters. Proliferating cells are
located in the outer three to five cell layers of a spheroid, and
quiescent cells reside more centrally. Such avascular spheroids
display density and metabolite gradients that hinder therapeutic
agents from reaching their target (Sutherland, 1988). Cancer
spheroids with diameters between 200 and 500 mm develop
gradients of oxygen, nutrients and catabolites, with a necrotic
core that is typically observed at sizes .500 mm (Hirschhaeuser
et al., 2010). The relevance of spheroids in the progression of
ovarian tumours has been reviewed elsewhere (Shield et al.,
2009). Interestingly, spheroids derived from peritoneal fluid of
patients with the advanced stages of the disease (FIGO III–IV;
see Box 1) range in number (from two tomore than 20) and size (from
30 to 750 mm in diameter), suggesting that there is a high patient-to-
patient variability (Burleson et al., 2004a; Casey et al., 2001).
The mechanism of formation of multicellular spheroids is still
not completely understood. Primary cancer cells can either detach
as single cells and then aggregate to form spheroids in order to
survive within the peritoneal cavity, or detach as cell sheets that
are assembled while free-floating in the peritoneal fluid. The
shedding of these multicellular masses might be more successful
for intraperitoneal dissemination and secretion of proteases,
which is required for migration and invasion into abdominal
lesions. It is also unknown whether primary cancer cells adhere
and invade into the secondary site (e.g. omentum, peritoneum) as
single cells or as spheroids, or whether they prepare these
secondary sites for successful colonisation (Lengyel, 2010; Moss
et al., 2009). Spheroids are distributed through a passive
mechanism as they are carried by the physiological force of the
peritoneal fluid to the secondary sites, following the ‘seed and
soil’ theory of non-random patterns of metastasis. Complex
interactions between tumour cells and their surrounding host cells
are crucial for tumorigenesis, whereby tumour cells (the ‘seed’)
target specific organs (the ‘soil’); hence, metastases only occur
when the ‘seed’ (i.e. ovarian cancer cells) and ‘soil’ (i.e.
mesothelium) are compatible (Fidler, 2003; Mathot and
Stenninger, 2012; Paget, 1889; Ribatti et al., 2006).
To experimentally model the growth of multicellular
spheroids, three-dimensional (3D) cell culture approaches have
been developed (Abbott, 2003; Lutolf and Hubbell, 2005;
Yamada and Cukierman, 2007). 3D cultures consist of cells
that are aggregated in spheroids, which harbour an intermediate
complexity and cellular heterogeneity between that of in vitro
monolayers and in vivo tumours. The importance of 3D
architecture and spheroid model systems has been extensively
reviewed and clearly illustrates that cell–matrix interactions are
better recreated by a complex aggregated cell population rather
than a simple cell monolayer (Bissell and Radisky, 2001;
Debnath and Brugge, 2005; Friedrich et al., 2007; Griffith and
Swartz, 2006; Hutmacher et al., 2010; Pampaloni et al., 2007).
However, the term spheroid is inconsistently used throughout the
literature, although its definition is crucial to the rationale of
spheroid-based experimental and mathematical modelling.
Spheroids comprise a defined 3D structure of uniform
geometry and physiological, non-linear gradients that can be
modulated, making them suitable for high-throughput, preclinical
drug screening routines (Hirschhaeuser et al., 2010).
Our group employs an interdisciplinary approach that aligns
bioengineered 3D cell culture platforms with molecular and cell
biology driven research to deliver a better understanding of cancer
progression, more reliable diagnostics and improved treatment
intervention (Hutmacher et al., 2010; Loessner et al., 2013;
Loessner et al., 2010). We applied this experimental 3D approach
to monitor gene expression profiles by using high-throughput
screening to analyse cancer-associated proteases (e.g. kallikrein-
related serine peptidases), the response to chemotherapeutics (e.g.
taxane-based agents) and stromal parameters (e.g. the presence of
mesothelial cells). We identified both known signalling pathways,
such as Wnt–b-catenin and integrin-mediated cascades, and
new pathways linked to tumorigenesis (D. Loessner, unpublished
observations).
The mechanical properties of bioengineered microenvironments
can be modified to study cellular behaviour; hence, they offer a
Box 1. Biology of ovarian cancer
There are four histological subtypes of epithelial ovarian cancer:
serous, endometrioid, clear cell and mucinous ovarian
adenocarcinoma. These are defined by their differentiation
status, with the serous subtype being the most frequent and
deadly. Each subtype is further grouped into: benign
(cystadenoma), malignant (carcinoma) and borderline (low-
malignant-potential), on the basis of their clinical behaviour.
Eschewing clinicopathological characteristics, two important
subcategories – low-grade and high-grade malignancies –
present alterations in ovarian cancer-associated genes and
pathways. Low-grade carcinomas are confined to the ovary with
an indolent clinical course, whereas high-grade tumours are
associated with an aggressive phenotype, occurrence of
metastasis and poor clinical outcome (Bast et al., 2009;
Cannistra, 2004; Shih and Davidson, 2009).
The staging system for ovarian cancer was defined by the
International Federation of Gynaecology and Obstetrics (FIGO)
according to the volume and extent of tumour spread. FIGO I–II
comprises the early stage, where the tumour is limited to one
or both ovaries (FIGO I) and other pelvic organs, such as uterus or
fallopian tubes (FIGO II). FIGO III–IV is defined as late-stage or
advanced disease, with involvement of the upper abdomen,
omentum or lymph nodes (FIGO III) and distant metastasis to
the liver or pleural space (FIGO IV) (Cannistra, 2004). Due to the
lack of specific symptoms in the early stages and effective
screening strategies, the majority of patients are diagnosed with
late stage disease (FIGO III–IV). The clinically established serum
marker cancer antigen 125 (CA-125, also known as mucin 16) is
elevated in ovarian cancer but often results in false positives, and
its sensitivity is very low to detect early stage disease, therapeutic
response and recurrence. The cancer-associated expression of
kallikrein-related peptidases (KLK), in particular KLK5, and the
human epididymis protein 4 (HE4, also known as WFDC2) are
promising complementary biomarkers for ovarian carcinoma (Dorn
et al., 2011; Hellstro¨m et al., 2003; Schummer et al., 2012; Yousef
and Diamandis, 2009; Yousef et al., 2003).
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distinct advantage over monolayer cultures (Butcher et al., 2009).
Loss of tissue homeostasis, reflected by an altered micro-rheology,
matrix stiffening, cell-generated and compression forces, is a
hallmark of disease. We were able to show that a uniform spheroid
formation correlates with microenvironmental stiffness and is
inversely associated with the mechanical properties of the
microenvironment (Loessner et al., 2010). Another group has
shown that the invasive behaviour of ovarian cancer cells is
inversely correlated with their stiffness, leading to cytoskeletal
remodelling and altered cell adhesion, which is indicative of a
progressive disease stage (Xu et al., 2012). However, these
mechanical properties were measured using individual cells,
whereas the stiffness of ovarian cancer spheroids or patient-
derived cancer cells has not been determined yet. Our preliminary
results suggest that spheroids and tumour tissue derived from
spheroid-based xenografts are softer than ovarian tissue (D.
Loessner, unpublished observations). Nevertheless, stiffness
might be a useful indicator of the metastatic potential of this
disease, although it is unknown whether or not cancer cells are
mechanically pre-conditioning their metastatic sites.
Experimental modelling of multicellular cancer
spheroids and their microenvironment
The main microenvironment for ovarian cancer cells is the
mesothelium, covering all organs of the peritoneum. The
mesothelium is a cell monolayer attached to a basement
membrane, which is predominantly composed of collagen types
I and IV, fibronectin and laminin. When disseminated spheroids
adhere to this secondary site, integrin a2b1-collagen type IV,
a5b1-fibronectin and a6b1-laminin interactions occur, which
promote the adhesion of cancer cells to the mesothelium. At the
same time, cancer-associated proteases degrade the basement
membrane and allow invasion of the mesothelium (Burleson et al.,
2004a; Casey et al., 2001; Kenny et al., 2008). It has been shown
that cancer cells do not directly adhere to mesothelial cells, but
rather to the underlying matrix. This spheroid–mesothelium
crosstalk occurs through integrin- and talin-dependent activation
of myosin, and contractile forces that are produced by spreading
cancer cells, thus mediating a displacement of mesothelial cells
from beneath the spheroids (Iwanicki et al., 2011).
Abnormal microenvironmental changes can stimulate cancerous
growth; in fact, inflammation associated with wound healing
mediates the development of epithelial tumours (Bissell and
Radisky, 2001). Tumours activate some of the normal wound-
healing cascades, such as the formation of a fibrin clot and the
release of growth factors (Dvorak, 1986). Hence, our group uses a
bioengineered microenvironment that mimics the fibrin clot to
provide the cancer cell niche during progression of ovarian cancer.
We developed an integrated 3D co-culture model of ovarian cancer
and mesothelial cells, which reflects the tumour–stroma
microenvironment of advanced-stage disease. Initial high-
throughput gene expression analyses and signalling profiling
show that spheroid growth is enhanced, and that genes regulating
cell cycle and growth are upregulated in 3D co-cultures,
highlighting the importance of tumour-stroma interactions in
disease progression (D. Loessner, unpublished observations).
Such spheroid-based co-culture models exhibit the cellular
heterogeneity of tumour tissues, and have become increasingly
useful 3D platforms (Hirschhaeuser et al., 2010; Iwanicki et al.,
2011; Meli et al., 2012; Schwartz and Chen, 2013) to deliver the
mechanobiological simulation parameters for computational
models with the aim of elucidating the factors that promote
tumour growth and treatment.
Continuum and discrete in silico techniques to
analyse tumour growth and treatment
Mathematical modelling in systems biology, from developmental
to cancer cell biology, already dates back to the mid-20th century
(Byrne, 2010; Tomlin and Axelrod, 2007). Over the past decades,
there has been substantial progress in experimental technologies
to obtain quantitative data from cell cultures and tissues, which
form the basis of the simulation parameters in a computational
model (Oates et al., 2009; Tomlin and Axelrod, 2007). Current
advances in microscopic imaging techniques and molecular
biology (Robinson et al., 2000) have provided a means by which
the existing ‘synthetic biology’ (Endler et al., 2009) community
can obtain detailed biological data to better inform model input
parameters and validate predictions of biological interactions that
occur from the cellular to the tissue level (Fig. 1).
Continuum modelling techniques
Continuum methods (see Box 2) have been used to predict
mechanisms of tumour initiation and growth (Chaplain, 1996;
Greenspan, 1976; Marcu et al., 2002; Please et al., 1998), and to
elucidate the relationship between tumour morphology and spatial
variations of microenvironmental parameters (Frieboes et al.,
2006). These in silico techniques can predict therapy outcomes
(e.g. cell-cycle and non-cell-cycle-specific therapeutics, hormone
therapy and radiotherapy), surgical efficacy and cancer cell
kinetics, thus being able to propose the therapeutic intervention
that yields the best possible patient outcome (Jain et al., 2011;
Kohandel et al., 2006; Marcu et al., 2005; Montalenti et al., 1998;
Panetta, 1997; Rockne et al., 2010).
Brown and Palmer used a probabilistic model (see Box 2) to
provide a novel simulation tool for the early detection of ovarian
cancer to predict survival and diagnosis of unsuspected ovarian
cancer, for which there is a lack of preclinical evidence for
ovarian cancer (Brown and Palmer, 2009). On the basis of this
model, a tumour needs more than four years to grow (FIGO I–II)
and one year to progress (FIGO III–IV) before it becomes
clinically apparent. Advanced-stage tumours (FIGO III–IV) start
to metastasise when they reach a diameter of 3 cm (Brown and
Palmer, 2009). To achieve a sensitivity of 50% in early detection
(FIGO I–II), the size of the tumour would need to be ,1.3 cm,
and to reduce the mortality rate by 50%, an early diagnostic
screen needs to be able to detect a tumour of ,0.5 cm in size.
Despite the challenge of estimating parameters, such as time and
size of the tumour, these simulations are in agreement with
clinical observations of the median diameter for advanced-stage
ovarian tumours, demonstrating the efficacy of this mathematical
approach.
Discrete modelling techniques
Continuum models do not provide resolution at the scale of
individual cells, which is an important feature of discrete and
hybrid models (see Box 2). Hybrid models represent cancer cells
discretely, and their host tissue (ECM), matrix-degrading
enzymes and nutrient concentrations (oxygen) as continuous
variables. Although this in silico technique might be limiting
because considerable computing power is required for large-scale
simulations, its advantage lies in the ability to predict the
complexity of intra- and intercellular interactions, and cell
Journal of Cell Science 126 (13)2764
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phenotypical traits that are guided by the local microenvironment
(Fig. 2).
Hybrid models have been used to investigate not only tumour
growth (Drasdo and Hohme, 2005; Jiang et al., 2005; Macklin
et al., 2010; Mansury et al., 2006; Stott et al., 1999), but also
tumour-induced angiogenesis (Anderson and Chaplain, 1998;
Macklin et al., 2009; Perfahl et al., 2011; Shirinifard et al.,
2009) and tumour morphology (Anderson et al., 2009; Anderson
et al., 2006). By their nature, these models incorporate spatial
variables that are associated with the tumour architecture. The
discrete representation of cells, which is inherent to hybrid
methods, has allowed predictions of cell–cell and cell–matrix
interactions, and tumour morphology, suggesting that a
heterogeneous ECM leads to an invasive, asymmetric
phenotype (Anderson et al., 2006). Simulations of the
mechanobiological impact on cell kinetics have indicated that
tumour growth is ‘biomechanically mediated’ during the later
phases of growth, and that biomechanical factors might alter cell
cycle phases and balance nutrient gradients at the spheroid
periphery (Drasdo and Ho¨hme, 2005; Macklin et al., 2009;
Mansury and Deisboeck, 2003). Hybrid methods have also been
used to infer potentially emerging behaviours, such as the
crosstalk between cancer cell signalling, proliferation and
invasion (Mansury and Deisboeck, 2003).
Simulating patient-specific outcomes
Patient-specific predictions of tumour growth, progression and
response to therapy are crucial because they are not generalised
to population-derived, representative parameters, but instead are
individualised to predict the outcome for a single person.
Recently, advanced experimental techniques that are capable of
providing sufficient detail to allow a patient-specific calibration
of model parameters have become available. Both discrete and
continuum approaches have been used to incorporate patient-
derived parameters and resulted in predictive potential of patient-
specific tumour growth (Dionysiou et al., 2006; Macklin et al.,
2012; Perfahl et al., 2011) and response to radiotherapy (Neal
et al., 2013; Rockne et al., 2010; Stamatakos et al., 2010).
Patient-derived details that are used to individualise these
models include 3D imaging of the tumour morphology, its
histopathology and its genetic characteristics (Dionysiou et al.,
2006; Neal et al., 2013; Rockne et al., 2010).
Finite element analysis
Finite element analysis (FEA) is a numerical method to simulate
the mechanical forces and internal stresses that act on physical
structures. This technique involves the discretization of a
complex solution domain (e.g. individual cells or multicellular
spheroids) into smaller regions. A solution is calculated for
equations that describe field variables in each of these
subregions, and the cumulative solution for these subregions
will provide a solution for the entire domain. This method has
been applied to the mechanical interactions between cells
(Brodland and Veldhuis, 2012a; Brodland and Veldhuis, 2012b;
Erdemir et al., 2012; Viens and Brodland, 2007; Wong and Tang,
2011; Yang and Brodland, 2009) and the surrounding matrix
(Koch et al., 2012). For instance, a cell-based FEA predicted that
intercellular mechanical forces of a particular type and magnitude
are crucial for cancer cell invasion (Brodland and Veldhuis,
2012b). In addition, a nanoscale FEA predicted that an increased
intracellular strain energy is associated with enhanced traction
forces and cell invasion (Koch et al., 2012).
In summary, a set of intricate cellular interactions characterise the
physiological context of tumour growth, and the complex crosstalk
of these processes spans multiple scales. Gaining a systems-level
understanding of these inter-relationships requires the definition and
management of multiple parameters over multiple scales, which is
often technically, if not economically, prohibitive to achieve
experimentally. Biologically based simulations allow the
simultaneous testing of multiple experimentally driven hypotheses
over a wide range of parameters, which is also very difficult to
achieve experimentally (Kam et al., 2012). In this context, in silico
modelling has the potential to improve our mechanistic
Box 2. Continuum, discrete and hybrid
mathematical modelling approaches in cancer
biology
There are recent augmentations of in silico techniques that have
opened a new focus on cancer research, such as agent-based
methods (ABM), which allow a more realistic simulation of cell
movement in arbitrary directions in contrast to other discrete
methods. Computational simulations of cancer cell behaviour
typically utilise either continuum or discrete methods (Byrne and
Drasdo, 2009) or a combination of both, known as a hybrid
technique (Anderson, 2005; Deisboeck et al., 2011; Kam et al.,
2012; Quaranta et al., 2005).
Continuum modelling approaches consider the tumour and/or
cellular microenvironments as a continuous medium, providing
resolution at the scale of an individual cell or multicellular
structures. These mathematical methods generally use partial
differential equations that incorporate growth and kinetic
interactions between species, and fluxes for active and passive
transport. By their nature, these models are deterministic, and a
key advantage is their success in simulating clinically sized
tumours. In the context of continuum approaches to cancer
simulation, probabilistic models incorporate statistical analysis
techniques to describe a relationship between model variables on
the basis of statistical relationships derived from historical data.
Discrete or cellular automaton modelling approaches permit
individual cells (or agents) to be represented explicitly, allowing
cell–cell interactions to be guided by a set of pre-defined rules and
permitting cell state to be tracked in space and time. Such models
are capable of representing cellular responses, such as intra- and
intercellular interactions, signalling pathways, cell polarity and the
influence of the tumour-stroma microenvironment on phenotypical
traits. Cellular automaton models permit the spatial verification of
these factors. Although there are several methods of cellular
automaton modelling that have been developed to simulate
physical, biological and scientific phenomena, in the context of
cancer biology, the most common method is the ABM. A key
feature of these models is their ability to provide lattice-free
representations of cells, thereby allowing cells to migrate in
arbitrary directions. The ‘cellular potts’ model has also been
applied to the study of tumour growth and provides an added level
of complexity by discretizing the actual cell, allowing cell volume
and shape to be represented specifically.
Hybrid modelling approaches combine both the continuum and
discrete approaches in order to incorporate the advantages of both
methods. When applied to cancer biology, this technique generally
incorporates continuum descriptions for the environmental and
population scale variables, such as nutrient concentration, coupled
with a discrete representation of the cells, which are then
influenced by variations in the continuum variables.
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understanding of tumour growth and treatment, to provide a means
to generate biological hypotheses and to inform experimental
design.
In silico modelling to predict disease progression
The microenvironmental signature of ovarian cancer progression
contains different regulatory components, such as pericellular
adhesions, tumour (ascites) fluid and the peritoneum. The
pericellular adhesive microenvironment is characterised by the
phenotypic plasticity of the ovarian surface epithelium and the
remodelling of integrins and cadherins during malignant
transformation, which facilitate metastatic dissemination and a
loss of cell polarity (see Box 3). Cancer cells within the
peritoneal fluid lack integrin–matrix contacts, but maintain
cadherin-mediated adhesions, and are exposed to diverse
soluble factors, such as growth factors, proteases or bioactive
fragments, which are secreted by both cancer and stromal cells,
and influence cell survival and motility. Upon peritoneal
anchorage, integrin–matrix adhesions are re-established, and
integrin-mediated signalling and proteolytic functions potentiate
metastatic outgrowth. However, our understanding of the
molecular and spatio-temporal regulation of these processes is
still incomplete. The design of experimental models that
accurately reflect the progressive disease is scientifically
challenging owing to the unique route of ovarian cancer
metastasis, the formation of multicellular spheroids. These
spheroids grow anchorage-independently and are resistant to
chemotherapy, which is indicative of specific survival
mechanisms (Barbolina et al., 2009; Dong et al., 2010; Moss
et al., 2009; Shield et al., 2009).
Microscale simulations that are capable of capturing the
biological, chemical and mechanical cues that control these
signalling pathways might shed light on the effect of cell polarity
components on cell function in malignant tissues. Simulations
that address individual cancer cells have attempted to capture the
inter-relationship between the cell cycle, cell–cell adhesions, the
surface density of cell receptors and chemotactic responses to
nutrient gradients (Anderson et al., 2009; Rejniak, 2005), and
have proposed roles for cadherin-mediated adhesions and related
signalling pathways (Ramis-Conde and Drasdo, 2012). However,
compared with predictions of multicellular cancer growth, the use
of in silico techniques to reproduce the complex cellular
dynamics that govern the behaviour of the cancer cells in their
microenvironment is still in its infancy. Nevertheless, with
advances in computational techniques, more detailed simulations
of these signalling cascades are being developed, which can be
verified with sophisticated experimental methods. Simulations of
the mechanical cues that regulate cellular processes have
demonstrated the dynamic nature of the mechanical strength of
focal adhesions, and that the cell can actively change these to
alter its migration velocity (Wong and Tang, 2011). However,
there are still knowledge gaps with regards to how mechanical
forces can influence intracellular processes (Gao et al., 2011;
Kim et al., 2011).
NANOSCALE
MICROSCALE
MACROSCALE
Microarray analysis
Pathway analysis
Cell receptor concentration
Cell proliferation or apoptosis index
Proportion in each cell cycle phase
Response to chemotactic stimuli
Response to chemotherapeutics
Growth analysis
Microscopy
Quantitative image analysis
Morphological analysis
Spheroid diameter or morphology
Cell proliferation or apoptosis index
Proportion in each cell cycle phase
Response to chemotactic stimuli
Response to chemotherapeutics
Spheroid diameter or morphology
Response to chemotherapeutics
Mathematical modellingExperimental modelling
Tissue or tumour
Cells
Genes
Immunohistochemistry
Organ
Proliferation
Polarity
Survival
Signal transduction
Gene expression
Transcription factors
Methods or techniques Methods or techniquesValidation or verificationFunctionScale
Probabilistic – Monte Carlo
Probabilistic – Kaplan Meir
CA or ABM, FEA
Diffusion equations
Growth models
Probabilistic – Taguchi
FEA
Diffusion equations
Probabilistic – Monte Carlo
Probabilistic – Taguchi
CA or ABM, FEA
Diffusion equations
Tissue microarray
Fig. 2. Illustration of a road map for multiscale alignment of experimental and mathematical modelling. Molecular processes that occur in the host and
tumour tissue at different cellular and genetic scales can be assessed using analytical and computational modelling techniques. Their interrelationship is ensured
through the combined validation and verification at each scale. The analysis of tumour tissues (marcoscale) involves immunohistochemistry and tissue
microarrays. Cellular changes (microscale) can be determined using growth analysis, microscopy, quantitative imaging and morphological analyses. Genetic
changes (nanoscale) can be quantified by microarray and pathway analyses. Diffusion equations simulate microenvironmental gradients (macro- and microscale)
and intracellular micro-constituents through the cytosol (nanoscale) as a continuum. Growth models predict tissue and/or tumour growth within organs that are
modified as a response to chemotherapeutics. Probabilistic techniques, such as the Taguchi, Monte Carlo or Kaplan Meir methods, describe the relationship
between model variables on the basis of statistical relationships derived from experimental data at multiple scales. Finite element analysis (FEA) is a numerical
method used to predict the tissue (macroscale), spheroid (microscale) mechanobiology and internal stresses (nanoscale) acting on physical structures. Cellular
automaton (CA) and agent-based methods (ABM) simulate spheroid morphology, cell surface receptor density, proliferation, cell cycle, response to chemotactic
stimuli and chemotherapeutics (both micro- and nanoscale).
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The metastatic route for ovarian cancer, as with other types of
cancer, is clearly a multiscale problem, because crucial events in
the metastatic outgrowth occur over multiple spatio-temporal
scales. These inter-relationships are intrinsically related to
multicellular cancer growth and invasion. Multiscale, hybrid
models that integrate cellular and tissue scales into a single
modelling framework permit simulations that better mimic
intracellular signalling pathways, intercellular mechanical
interactions and microenvironmental variables to ultimately
predict disease progression (Anderson and Quaranta, 2008;
Chakrabarti et al., 2012).
In silico modelling of breast and prostate cancers
Mathematical models have been employed for other spheroid-
forming tumour cells, such as breast and prostate cancer, which are
hormone-dependent diseases, as is ovarian cancer. The multiscale
modelling of breast cancer initiation, invasion, metastasis,
angiogenesis, its microenvironment and advances of
experimental approaches have been reviewed elsewhere
(Chakrabarti et al., 2012). Multiscale, agent-based methods
(ABM) were combined with signalling pathways to address
basic research questions and to identify novel molecular
targets (Chakrabarti et al., 2012). The inclusion of multiple cell
types and reaction-diffusion equations reflected the tumour–
stroma microenvironment. Such an in silico strategy is useful to
simulate subcellular ovarian cancer networks, microenvironmental
gradients within the peritoneal fluid and the distribution of
chemotherapeutics.
Of particular interest is a computed morphometric approach
to identify molecular predictors of phenotypes, which uses
multidimensional profiling of spheroid morphologies on the basis
of 3D culture imaging and genetic analyses of breast cancer cells
(Han et al., 2010). The prediction of spheroid architectures that is
based on specific gene expression patterns uses a consensus matrix
and hierarchical clustering. The benefit of this method is that
consensus clustering, which informs about the stability of identified
subpopulations, is combined with a cumulative distribution function
to determine the number and shape of these subpopulations (Han
et al., 2010). This in silico strategy is beneficial for molecular
subtyping of ovarian cancer spheroids to investigate therapy
response factors that are differentially expressed in subpopulations
upon anti-cancer treatment.
Computational network modelling has provided a systems view
of dysregulated cascades and oncogenic mutations in metastatic
breast cancer (Kreeger and Lauffenburger, 2010). This approach
addressed the multivariate nature of the genetic, molecular and
cellular network changes that are associated with cancerous
diseases. As such, genomic mutations can cause alterations in
protein–protein interactions, which lead to altered signalling
pathways and cellular behaviour. The advances of this approach
are in the integration of predictive methods, such as correlative
regression, statistical factor and differential equation analyses,
and mutual information-based algorithms, with quantitative
experimental data to decipher cancer-related pathways and the
efficacy of therapies (Kreeger and Lauffenburger, 2010). This in
silico strategy is useful to simulate networks that are dependent on
ovarian cancer-specific mutations.
ABM approaches incorporated patient-specific parameters for
cell morphology, density, duct architecture, proliferative and
apoptotic indices from pre-surgical patient biopsies (Edgerton
et al., 2011; Hyun and Macklin, 2013; Macklin et al., 2012;
Macklin et al., 2010). These simulations use patient-derived
tissues, including growth and death indices before and after
chemotherapy, and thus can support the decision-making process
for individual response rates.
For prostate cancer, two mathematical approaches have been
employed; a continuum model to quantitatively describe
biomarker dynamics and a Monte Carlo strategy (probabilistic
method) to identify hormone-dependent signalling parameters
(Swanson et al., 2003; Tasseff et al., 2010). The continuum
model combined the serum prostate-specific antigen level, which
is linked to prostate cancer growth, and quantified this level in a
simple equation that predicted its production and loss. The
prostate-specific antigen was predicted to increase in benign and
malignant prostate cells, underlining the biological relevance of
this method (Swanson et al., 2003). Such an in silico strategy can
also be used to simulate the dynamics of the serum marker CA-
125 (see Box 1).
The authors of the second study investigated androgen-
dependent molecular networks in metastatic prostate cancer,
and their mechanistic mathematical model was on the basis of
mass action kinetic processes within an ordinary differential
Box 3. Ovarian cancer cell polarity
Epithelial cells maintain physical contact and polarity with their
neighbours through adherens, gap and tight junctions and
desmosomes. A loss of cell contacts and polarity is a hallmark of
tumorigenesis (Bissell and Radisky, 2001). Modulation of adherens
junctions can promote disease progression upon downregulation of
E-cadherin (Cowden Dahl et al., 2008; D’Souza-Schorey, 2005;
Martin-Belmonte and Perez-Moreno, 2012). However, cellular
responses are context-dependent; in fact, gain of E-Cadherin
expression is an early step in ovarian cancer (Hudson et al., 2008).
Cadherins form complexes with catenins, which support cell polarity
and cytoskeletal organisation (Weis andNelson, 2006; Yamada et al.,
2005), and, upon disruption of the complex, b-catenin translocates
into the nucleus. Nuclear b-catenin is linked to high-grade disease
(Barbolina et al., 2011). Connexins, such as Cx43, act as tumour
suppressors because the loss of junctional networks enables cancer
cells to circumvent growth regulation upon drug treatment (Gershon
et al., 2008; Toler et al., 2006). Claudin-3, claudin-4 and claudin-7 are
highly upregulated in ovarian cancer and are associated with
increased invasiveness, which is indicative of a metastatic
phenotype (Agarwal et al., 2005; Dahiya et al., 2011). Claudin-3
represents a potential biomarker to complement CA-125 in detection
of this disease (Morin, 2007). Desmosomes have a function in
disease progression and Wnt–b-catenin signalling (Chidgey and
Dawson, 2007; Green and Gaudry, 2000; Miao et al., 2008). The
atypical proteinase kinase C is linked to defects in cell polarity and
decreased progression-free patient survival, which is indicative of an
aggressive phenotype (Eder et al., 2005).
The formation of polarized structures within 3D cultures is linked
to cancer cell survival by blocking drug-induced apoptosis
(Debnath and Brugge, 2005). Integrin a6 is highly expressed in
ovarian cancer cells, and its inhibition prevents cell growth (Ahmed
et al., 2005). Integrin a6b4 is associated with tumorigenesis
because its expression persists in invasive cancer cells, which no
longer form stable cell junctions (Alper et al., 2001). The loss of
cell polarity results in an altered spatial distribution of receptor
tyrosine kinases, leading to receptor dimerisation and activation by
ligands that are normally not available to induce aberrant signalling
in polarized cells (Casaletto and McClatchey, 2012).
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equation framework, including gene and protein expression
levels (Tasseff et al., 2010). They assume spatial homogeneity,
whereas cytosolic and membrane-localised processes are
differentiated. Using this approach, several transcription factors
and signalling pathways are found to be androgen-independent,
thus providing novel treatment options for androgen-insensitive
prostate cancers (Tasseff et al., 2010). This in silico strategy is
useful to predict changes in signalling cascades in ovarian cancer
cells that are responsive to the anti-cancer treatment employed
and microenvironmental parameters (e.g. hydrogel stiffness and
co-cultures with stromal cells).
Another biochemically based mathematical model of anti-
androgen therapy dissected the heterogeneity of prostate cancer
progression, and is suitable as a predictive tool when personalised
parameters are incorporated (Jain et al., 2011). Here, the
personalised input parameters address the dynamics of cancer
growth and progression, including that of healthy prostate cells,
androgen-dependent and castrate-resistant cancer cells. These
parameters include the turnover rate of patient-derived cancer
cells, testosterone and prostate-specific antigen levels, the
frequency of mutation from androgen-dependent to castration-
dependent prostate cancer cells and the mutated-cell doubling
time. This approach modelled the outcome of either continuous
or intermittent treatment and predicted that continuous therapy
leads to a disease-free survival of up to five years, whereas an
observed increase in androgen-dependent cancer cells suggests
that intermittent therapy promotes androgen resistance. As this in
silico strategy is based on patient-derived data, it could be used as
a personalised prognostic tool (Jain et al., 2011). These
computational modelling approaches for breast and prostate
cancer further demonstrate the usefulness of in silico techniques
in simulating cancer cell behaviour.
Areas in need of advancement
There is a clear need to improve our current knowledge of the
processes underlying the pathogenesis of ovarian cancer to
develop more effective, anti-metastatic therapies, thus aligning
experimental and simulation approaches. As ovarian cancer is a
rather rare malignancy, accounting for 3% of all female cancers
in the United States (Siegel et al., 2012), there are limited
opportunities for large clinical trials. Hence, interdisciplinary
approaches that combine bioengineered 3D cancer models with
computer-based predictions, which integrate multiscale and
patient-specific parameters, and with preclinical drug screening
tools will be highly beneficial in designing clinical studies.
Multiscale modelling approaches
Experimental testing of computer-generated hypotheses is not
trivial, because it requires an open mind from the scientist and the
development of new quantitative methods (Anderson and
Quaranta, 2008). There is currently a lack of simulation-based
methods to describe the unique metastatic behaviour of ovarian
cancer. The molecular processes within multicellular spheroids
need to be integrated with those that occur in the host tissue at the
genetic, cellular and organelle level (Fig. 2). Our own
mathematical simulations are focused on the design of a
multiscale, ovarian cancer model that incorporates the
mechanobiological effects of interactions between cancer cells
and their microenvironment, and cell–cell adhesions. Such a
model uses both hybrid-ABM and multiphase FEA techniques;
cellular dynamics and signalling cascades are integrated using a
hybrid-ABM approach. To validate our experimental data, we
have recently established a spheroid-based ovarian cancer animal
model to replicate the peritoneal outgrowth, which reflects the
disease progression seen in patients. This intraperitoneal animal
model is also suited to screen anti-metastatic therapeutics and,
moreover, employs a number of cells (105) that is physiologically
more relevant than the cell number currently used in other animal
models (cell numbers 106–107; Loessner et al., 2013). However,
the learning curve is steep, and extensive investments of time and
money are required before a truly integrated, multi-disciplinary
approach to in silico, ex vivo and in vivo approaches can be
realised. Table 1 outlines the costs for an incremental experiment
in a mature laboratory that already works in this interdisciplinary
area. In silico modelling requires a mathematician, relatively low
costs and time investment, whereas an ex vivo spheroid-based
study needs to be conducted by an experienced experimentalist
over several weeks and is ten times more expensive than the in
silico approach. However, a spheroid-based animal study will last
several months, and is both cost and labour-intensive (Loessner
et al., 2013).
Patient-specific calibration of in silico models
The use of patient-specific parameters in mathematical models of
biological systems is clinically very relevant. To translate
multiscale simulations of cancer cell dynamics into clinical
assessments, patient-derived data from in situ tissues and
databanks (e.g. therapy response and survival time) are
integrated into modelling parameters (Graf, 2011). These
models not only broaden the understanding of cellular
processes at the systems level, but might also provide a
Table 1. Summary of time and costs for one established spheroid-based in silico, ex vivo and in vivo study. Estimates are
calculated on the basis of one incremental modelling experiment performed by an experienced mathematician and scientist
Time and costs In silico study Ex vivo study In vivo study
Duration of study 1 week 4 weeks 16 weeks
Personnel $1500 $6000 $24,000
Laboratory supplies N/A $3000 $2000
Laboratory animals (includes
housing costs)
N/A N/A $3000
Imaging services N/A $1000 $1000
Gene expression analyses N/A $3500 $3500
Protein expression analyses N/A $1000 $2000
Total costs $1500 $14,500 $35,500
N/A, non-applicable; costs in US$.
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diagnostic tool for disease progression and a therapeutic tool for
improving efficacy of therapy (Konukoglu et al., 2010). For
example, magnetic resonance imaging of brain tumours to
analyse the temporal changes in tumour shape have provided
continuum simulation parameters to predict the growth
characteristics for an individual patient (Konukoglu et al.,
2010). In addition, the inclusion of histopathological data into
simulations can estimate the response to therapy (Stamatakos,
2011; Stamatakos et al., 2010). An inherent assumption in such
patient-specific modelling is that the simulation technique
applied (see Box 2) is the most appropriate for the problem
being investigated. To address this limitation, simulations need to
be verified to ensure their validity within the constraints of the
known solution space, and their robustness when tested outside
the solution domain.
Conclusions
The development of experimentally verified predictions is one key
element for personalised medicine that harbours anatomical,
physiological, and molecular factors to give a deeper
understanding of the responses of cancerous tissues to
mechanobiological stimuli. Given that there are still open
questions regarding the biological processes that are associated
with metastasis, including how the dissociation of primary tumour
cells, the formation of multicellular spheroids, cancer cell invasion
at the secondary site and chemoresistance occur, the
implementation of computer-based algorithms, which accurately
capture all aspects of the metastatic route, is far from being
realised. However, the strength in applying a hybrid-ABM,
multiphase FEA approach is to improve our current knowledge
of ovarian cancer in order to test new hypotheses, or to ascertain
signalling avenues that can highlight directions for future
experimental and clinical studies. Hence, the road map presented
here will be the next step in an important undertaking to determine
the unique regulatory signatures of ovarian cancer progression, and
uses an in silicomodel that has been validated with spheroid-based
ex vivo and in vivo models. Ultimately, we anticipate that such an
approach will allow us to uncover predictive and prognostic
biomarkers, and thus lead to new therapeutic interventions.
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